IL1B and type 1 diabetes mellitus: Since our research was performed to better understand the natural history of the condition type 1 diabetes mellitus in the context of IL-1β levels, the inclusion of treatment/interventionist studies (which, by definition, try to decrease the chronic inflammation in diabetes or to eliminate risk factors) could potentially distort the reality of this disease, attenuate inflammation, modulate il-1β levels, introduce a new heterogeneity source, and, consequently, affecting the achievement of our goals.